Dutch biotechnology company Mucosis B.V. today announced the appointment of Dr. Govert Schouten to the position of Chief Executive Officer.
“We are very pleased to have a person with Dr. Schouten’s business and strategic background join Mucosis,” said Dr. Willem Hazenberg, chairman of the supervisory board of Mucosis and partner at Mucosis’s lead investor BioGeneration Ventures B.V. “His extensive experience in the vaccine industry will make an important contribution to Mucosis’s ambitious growth strategy for the coming years”.
Prior to joining Mucosis, Dr. Schouten served as vice president business development at publicly traded Crucell N.V. He was responsible for many of Crucell’s vaccine development partnerships, and for the successful licensing of Crucell’s technologies to the vaccine industry. Dr. Schouten holds an M.Sc in Biomedical Sciences and a Ph.D. in Virology from Leiden University.
For further information please contact: Dr. Willem Hazenberg BioGeneration Ventures B.V. Tel: +31 (35) 6993000 hazenberg@mucosis.com www.mucosis.com
About Mucosis Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal vaccines that can be applied via the nose or mouth. Mucosis’s lead product candidate is FluGEM™, an intranasal vaccine to prevent influenza. Mucosis’s vaccines are based on the patented Mimopath™ technology. Vaccines based on this technology can be administered needle-free, raise a more natural immune response, and provide a broader base of protection.
About Mimopath™ technology Mimopath™ technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed an easy technique to formulate the L. lactis bacteria into particles that can be loaded with antigens from viral, bacterial or parasitic origin. The antigen-covered particles form a vaccine that can be delivered via the nose or mouth, without the need for a needle. These vaccine particles raise protective immunity by activation of both the innate and adaptive immune system.
